Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/30/2872188/0/en/Sutro-Biopharma-Announces-Initiation-of-Randomized-Portion-Part-2-of-REFR%CE%B1ME-O1-Trial.html
https://www.ipsen.com/press-releases/ipsen-and-sutro-biopharma-announce-exclusive-global-licensing-agreement-for-an-adc-targeting-solid-tumors/
https://www.globenewswire.com/news-release/2024/04/02/2855747/0/en/Sutro-Biopharma-Announces-Pricing-of-75-Million-Underwritten-Offering.html
https://www.globenewswire.com/news-release/2024/03/25/2852012/0/en/Sutro-Biopharma-Reports-Full-Year-2023-Financial-Results-Business-Highlights-and-Select-Anticipated-Milestones.html
https://www.globenewswire.com//news-release/2024/02/06/2824717/0/en/Sutro-Biopharma-to-Participate-in-Upcoming-Investor-Conferences.html
https://www.globenewswire.com//news-release/2024/01/04/2804329/0/en/Sutro-Biopharma-Highlights-Potential-Multi-Cancer-Opportunity-for-Luvelta-a-FolR%CE%B1-targeting-ADC.html
https://www.globenewswire.com//news-release/2023/12/14/2796695/0/en/Sutro-Biopharma-to-Host-Investor-Webcast-Highlighting-Potential-Multi-Cancer-Opportunity-for-Luvelta-a-FolR%CE%B1-targeted-ADC-on-January-4-2024.html
https://www.globenewswire.com//news-release/2023/12/11/2794266/0/en/Sutro-Biopharma-Announces-New-Positive-Data-from-the-Compassionate-Use-of-Luveltamab-Tazevibulin-luvelta-in-Pediatric-Patients-with-Relapsed-Refractory-CBF-GLIS-Presented-at-ASH-20.html
https://www.globenewswire.com//news-release/2023/12/04/2790443/0/en/Sutro-Biopharma-to-Participate-in-the-JMP-Securities-Hematology-and-Oncology-Summit.html
https://www.globenewswire.com//news-release/2023/11/27/2786509/0/en/Vaxcyte-Exercises-Option-and-Enters-into-Manufacturing-Rights-Agreement-with-Sutro-Biopharma-to-Obtain-Control-Over-Manufacturing-and-Development-of-Cell-Free-Extract-for-its-Vacci.html